We are live on ! Find out more
TCM

Tenor Capital Management Portfolio holdings

AUM $6.49B
1-Year Est. Return 3%
This Fund
S&P 500
This Quarter Est. Return
+0.34%
1 Year Est. Return
+3%
3 Year Est. Return
+3.9%
5 Year Est. Return
+4.41%
10 Year Est. Return
+12.14%
AUM
$4.2B
AUM Growth
-$165M
Cap. Flow
-$3.21B
Cap. Flow %
-76.56%
Top 10 Hldgs %
30.92%
Holding
842
New
9
Increased
5
Reduced
2
Closed
210
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KVSC
126
DELISTED
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
$1.52M 0.04%
152,540
SCOB
127
DELISTED
ScION Tech Growth II Class A Ordinary Shares
SCOB
$1.52M 0.04%
150,000
SVFA
128
DELISTED
SVF Investment Corp. Class A Ordinary Shares
SVFA
$1.52M 0.04%
150,000
FTEV
129
DELISTED
FinTech Evolution Acquisition Group
FTEV
$1.51M 0.04%
150,000
CLAA
130
DELISTED
Colonnade Acquisition Corp. II
CLAA
$1.51M 0.04%
150,000
COCH icon
131
Envoy Medical
COCH
$51.7M
$1.5M 0.04%
150,000
TRTL
132
DELISTED
TortoiseEcofin Acquisition Corp. III
TRTL
$1.49M 0.04%
150,000
DGNU
133
DELISTED
Dragoneer Growth Opportunities Corp. III Class A Ordinary Shares
DGNU
$1.48M 0.04%
150,000
BIOT
134
DELISTED
Biotech Acquisition Company Class A Ordinary Shares
BIOT
$1.45M 0.03%
143,758
OKLO
135
Oklo
OKLO
$8.42B
$1.4M 0.03%
140,992
KRNL
136
DELISTED
Kernel Group Holdings, Inc. Class A Ordinary Shares
KRNL
$1.33M 0.03%
131,941
NFNT
137
DELISTED
Infinite Acquisition Corp.
NFNT
$1.28M 0.03%
125,000
TGAA
138
DELISTED
Target Global Acquisition I Corp. Class A Ordinary Share
TGAA
$1.28M 0.03%
125,000
VMGA
139
DELISTED
VMG Consumer Acquisition Corp. Class A Common Stock
VMGA
$1.27M 0.03%
125,000
ARYE
140
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$1.27M 0.03%
125,700
TZPS
141
DELISTED
TZP Strategies Acquisition Corp. Class A Ordinary Share
TZPS
$1.12M 0.03%
110,396
BNAI
142
Brand Engagement Network
BNAI
$95.3M
$1.11M 0.03%
11,000
QDRO
143
DELISTED
Quadro Acquisition One Corp. Class A Ordinary Shares
QDRO
$1.1M 0.03%
109,291
GOGN
144
DELISTED
GoGreen Investments Corporation
GOGN
$1.04M 0.02%
100,000
CITE
145
DELISTED
Cartica Acquisition Corp Class A Ordinary Shares
CITE
$1.04M 0.02%
100,000
ROSE
146
DELISTED
Rose Hill Acquisition Corporation Class A Ordinary Shares
ROSE
$1.03M 0.02%
100,000
TRAQ
147
DELISTED
Trine II Acquisition Corp.
TRAQ
$1.03M 0.02%
100,000
CBRG
148
DELISTED
Chain Bridge I Class A Ordinary Shares
CBRG
$1.03M 0.02%
100,000
GTAC
149
DELISTED
Global Technology Acquisition Corp. I Class A Ordinary Shares
GTAC
$1.03M 0.02%
100,000
CERO
150
DELISTED
CERo Therapeutics
CERO
$1.03M 0.02%
50

Similar funds

Tenor Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Tenor Capital Management held 842 positions worth $4.2B, down 3.8% from $4.36B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Tenor Capital Management withdrew a net $3.21B in Q4 2022, closing 210 positions and reducing 2 holdings. Its most notable exit was Future Health ESG Corp. Common stock, an estimated $9.81M position sold in full.

By sector, the portfolio is most concentrated in Financials at 11% of assets, down from 15% a quarter earlier, followed by Industrials and Technology.

Against the trend, Tenor Capital Management opened a new position in Activision Blizzard worth $1.01M.

  • Tenor Capital Management's largest Q4 2022 buy was Activision Blizzard: 13,200 shares worth $1.01M.
  • Tenor Capital Management added most to Pagaya Technologies Ltd Warrants in Q4 2022, an estimated $0 increase.
  • Tenor Capital Management's biggest Q4 2022 reduction was Esperion Therapeutics, cutting an estimated $1.21M.
  • Tenor Capital Management fully exited Future Health ESG Corp. Common stock in Q4 2022, selling an estimated $9.81M.
  • Tenor Capital Management's ten largest holdings make up 31% of its $4.2B portfolio in Q4 2022.
  • Tenor Capital Management opened 9 new positions and closed 210 in Q4 2022.
  • Tenor Capital Management's portfolio value fell 3.8% quarter-over-quarter to $4.2B.

Based on Tenor Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.